Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Emergency Service, Hospital | 15 | 2023 | 255 | 2.780 |
Why?
|
| Ultrasonography | 15 | 2025 | 227 | 2.430 |
Why?
|
| Point-of-Care Systems | 6 | 2025 | 58 | 2.060 |
Why?
|
| Abscess | 4 | 2020 | 28 | 1.960 |
Why?
|
| Soft Tissue Infections | 3 | 2020 | 23 | 1.780 |
Why?
|
| Fibrinolytic Agents | 2 | 2025 | 59 | 1.630 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2020 | 17 | 1.300 |
Why?
|
| Humans | 53 | 2025 | 27072 | 1.290 |
Why?
|
| Heart Arrest | 2 | 2020 | 39 | 1.250 |
Why?
|
| Anti-Bacterial Agents | 6 | 2021 | 370 | 1.250 |
Why?
|
| Shoulder Dislocation | 2 | 2022 | 111 | 1.210 |
Why?
|
| Trachea | 4 | 2025 | 46 | 1.170 |
Why?
|
| Warfarin | 3 | 2022 | 25 | 1.010 |
Why?
|
| Intubation, Intratracheal | 4 | 2025 | 94 | 0.980 |
Why?
|
| Thrombectomy | 1 | 2025 | 33 | 0.940 |
Why?
|
| Endovascular Procedures | 1 | 2025 | 33 | 0.930 |
Why?
|
| Thrombolytic Therapy | 1 | 2025 | 48 | 0.920 |
Why?
|
| Hyperkalemia | 2 | 2021 | 4 | 0.880 |
Why?
|
| Acute Kidney Injury | 2 | 2021 | 38 | 0.880 |
Why?
|
| Blood Coagulation Factors | 3 | 2022 | 19 | 0.880 |
Why?
|
| Drainage | 3 | 2020 | 39 | 0.870 |
Why?
|
| Fractures, Bone | 2 | 2022 | 73 | 0.860 |
Why?
|
| Esophagus | 3 | 2022 | 63 | 0.840 |
Why?
|
| Retrospective Studies | 18 | 2023 | 3538 | 0.840 |
Why?
|
| Ventricular Fibrillation | 2 | 2020 | 14 | 0.820 |
Why?
|
| Hemorrhage | 2 | 2020 | 81 | 0.810 |
Why?
|
| Antiemetics | 1 | 2022 | 9 | 0.780 |
Why?
|
| Hypoglycemia | 2 | 2021 | 12 | 0.770 |
Why?
|
| Sympathomimetics | 1 | 2021 | 5 | 0.760 |
Why?
|
| Critical Illness | 3 | 2021 | 117 | 0.760 |
Why?
|
| Pharmacy Service, Hospital | 2 | 2020 | 12 | 0.750 |
Why?
|
| Airway Management | 1 | 2021 | 15 | 0.750 |
Why?
|
| Ketamine | 1 | 2021 | 25 | 0.740 |
Why?
|
| Emergency Medicine | 2 | 2020 | 94 | 0.740 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2021 | 42 | 0.730 |
Why?
|
| Antihypertensive Agents | 1 | 2021 | 55 | 0.720 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 44 | 0.700 |
Why?
|
| Allied Health Personnel | 1 | 2020 | 7 | 0.700 |
Why?
|
| Phenytoin | 1 | 2020 | 6 | 0.690 |
Why?
|
| Efficiency, Organizational | 1 | 2020 | 15 | 0.690 |
Why?
|
| Bites and Stings | 1 | 2020 | 3 | 0.690 |
Why?
|
| Wound Infection | 1 | 2020 | 5 | 0.690 |
Why?
|
| Documentation | 1 | 2020 | 24 | 0.690 |
Why?
|
| Skin Diseases | 1 | 2020 | 25 | 0.690 |
Why?
|
| Status Epilepticus | 1 | 2020 | 13 | 0.690 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2025 | 292 | 0.690 |
Why?
|
| Inappropriate Prescribing | 1 | 2020 | 5 | 0.690 |
Why?
|
| Anticonvulsants | 1 | 2020 | 56 | 0.670 |
Why?
|
| Adult | 15 | 2025 | 7831 | 0.670 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2019 | 26 | 0.660 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 25 | 0.660 |
Why?
|
| Gonorrhea | 1 | 2019 | 7 | 0.640 |
Why?
|
| Chlamydia Infections | 1 | 2019 | 7 | 0.640 |
Why?
|
| Glucagon | 1 | 2019 | 7 | 0.630 |
Why?
|
| Gastrointestinal Agents | 1 | 2019 | 11 | 0.630 |
Why?
|
| Aftercare | 1 | 2019 | 24 | 0.630 |
Why?
|
| Retinal Detachment | 1 | 2019 | 7 | 0.630 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 145 | 0.620 |
Why?
|
| Pulmonary Edema | 3 | 2023 | 26 | 0.620 |
Why?
|
| Male | 18 | 2023 | 14772 | 0.620 |
Why?
|
| Epistaxis | 1 | 2018 | 9 | 0.620 |
Why?
|
| Foreign Bodies | 1 | 2019 | 26 | 0.610 |
Why?
|
| Antifibrinolytic Agents | 1 | 2018 | 17 | 0.610 |
Why?
|
| Spinal Puncture | 1 | 2018 | 25 | 0.600 |
Why?
|
| Tranexamic Acid | 1 | 2018 | 17 | 0.600 |
Why?
|
| Skin Diseases, Infectious | 1 | 2018 | 6 | 0.590 |
Why?
|
| Anthrax | 1 | 2017 | 1 | 0.580 |
Why?
|
| Transportation of Patients | 1 | 2017 | 3 | 0.580 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2017 | 3 | 0.580 |
Why?
|
| Ultrasonography, Interventional | 1 | 2018 | 69 | 0.570 |
Why?
|
| Mass Casualty Incidents | 1 | 2017 | 5 | 0.570 |
Why?
|
| Health Resources | 1 | 2017 | 23 | 0.570 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2017 | 30 | 0.570 |
Why?
|
| Emergency Medical Services | 1 | 2017 | 28 | 0.560 |
Why?
|
| Female | 17 | 2023 | 15212 | 0.560 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 317 | 0.550 |
Why?
|
| Anticoagulants | 3 | 2022 | 87 | 0.500 |
Why?
|
| Sensitivity and Specificity | 7 | 2025 | 482 | 0.500 |
Why?
|
| Middle Aged | 13 | 2023 | 8923 | 0.490 |
Why?
|
| Azoles | 1 | 2014 | 1 | 0.460 |
Why?
|
| Tacrolimus | 1 | 2014 | 15 | 0.460 |
Why?
|
| Sirolimus | 1 | 2014 | 19 | 0.450 |
Why?
|
| Antifungal Agents | 1 | 2014 | 43 | 0.440 |
Why?
|
| Treatment Failure | 3 | 2020 | 158 | 0.440 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 120 | 0.420 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 109 | 0.410 |
Why?
|
| Atrial Fibrillation | 3 | 2020 | 131 | 0.400 |
Why?
|
| Algorithms | 1 | 2014 | 350 | 0.380 |
Why?
|
| Pneumonia, Staphylococcal | 2 | 2021 | 9 | 0.360 |
Why?
|
| Treatment Outcome | 5 | 2020 | 3485 | 0.360 |
Why?
|
| Metoprolol | 3 | 2020 | 6 | 0.360 |
Why?
|
| Prospective Studies | 5 | 2023 | 1778 | 0.360 |
Why?
|
| Diltiazem | 3 | 2020 | 8 | 0.360 |
Why?
|
| Aged | 9 | 2025 | 8997 | 0.360 |
Why?
|
| Pharmacists | 2 | 2021 | 16 | 0.360 |
Why?
|
| Intestinal Obstruction | 2 | 2023 | 11 | 0.350 |
Why?
|
| Intensive Care Units | 3 | 2021 | 261 | 0.330 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2020 | 35 | 0.320 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2021 | 119 | 0.320 |
Why?
|
| Insulin | 2 | 2021 | 89 | 0.310 |
Why?
|
| Heart Failure | 2 | 2018 | 151 | 0.260 |
Why?
|
| International Normalized Ratio | 3 | 2022 | 16 | 0.260 |
Why?
|
| Vomiting | 2 | 2023 | 17 | 0.250 |
Why?
|
| Nausea | 2 | 2023 | 24 | 0.250 |
Why?
|
| Point-of-Care Testing | 2 | 2023 | 29 | 0.240 |
Why?
|
| Child | 2 | 2020 | 1295 | 0.240 |
Why?
|
| Chicago | 2 | 2019 | 949 | 0.240 |
Why?
|
| Bias | 1 | 2025 | 32 | 0.240 |
Why?
|
| Intracranial Hemorrhages | 1 | 2025 | 13 | 0.240 |
Why?
|
| Diverticulitis | 1 | 2025 | 5 | 0.240 |
Why?
|
| Nasal Cavity | 2 | 2021 | 32 | 0.220 |
Why?
|
| Nystagmus, Pathologic | 1 | 2023 | 2 | 0.220 |
Why?
|
| Potassium | 2 | 2021 | 62 | 0.220 |
Why?
|
| Dizziness | 1 | 2023 | 18 | 0.220 |
Why?
|
| Vancomycin | 2 | 2021 | 52 | 0.210 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 161 | 0.210 |
Why?
|
| Blood Glucose | 2 | 2021 | 104 | 0.210 |
Why?
|
| Eye | 1 | 2022 | 7 | 0.200 |
Why?
|
| Metoclopramide | 1 | 2022 | 4 | 0.200 |
Why?
|
| Thrombosis | 2 | 2020 | 54 | 0.200 |
Why?
|
| Neuroimaging | 1 | 2022 | 126 | 0.190 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 261 | 0.190 |
Why?
|
| Cystitis | 1 | 2021 | 12 | 0.190 |
Why?
|
| Stroke Volume | 2 | 2018 | 54 | 0.180 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 34 | 0.180 |
Why?
|
| Urinary Tract Infections | 1 | 2021 | 31 | 0.180 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 22 | 0.180 |
Why?
|
| Publications | 1 | 2020 | 16 | 0.180 |
Why?
|
| Hypercalcemia | 1 | 2020 | 9 | 0.170 |
Why?
|
| Job Satisfaction | 1 | 2020 | 14 | 0.170 |
Why?
|
| Piracetam | 1 | 2020 | 8 | 0.170 |
Why?
|
| Cardiovascular Agents | 1 | 2020 | 24 | 0.170 |
Why?
|
| Calcitonin | 1 | 2020 | 16 | 0.170 |
Why?
|
| Diphosphonates | 1 | 2020 | 19 | 0.170 |
Why?
|
| Benzodiazepines | 1 | 2020 | 46 | 0.170 |
Why?
|
| Blood Coagulation | 1 | 2020 | 20 | 0.170 |
Why?
|
| Publishing | 1 | 2020 | 34 | 0.170 |
Why?
|
| Dogs | 1 | 2020 | 167 | 0.170 |
Why?
|
| Cellulitis | 1 | 2020 | 10 | 0.170 |
Why?
|
| Seizures | 1 | 2020 | 67 | 0.170 |
Why?
|
| Young Adult | 2 | 2017 | 1994 | 0.160 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2020 | 65 | 0.160 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2019 | 4 | 0.160 |
Why?
|
| Chlamydia trachomatis | 1 | 2019 | 6 | 0.160 |
Why?
|
| Blood Pressure | 1 | 2020 | 195 | 0.160 |
Why?
|
| Midodrine | 1 | 2019 | 4 | 0.160 |
Why?
|
| Shock | 1 | 2019 | 9 | 0.160 |
Why?
|
| Mass Screening | 1 | 2021 | 167 | 0.160 |
Why?
|
| Bezoars | 1 | 2019 | 3 | 0.160 |
Why?
|
| Peristalsis | 1 | 2019 | 12 | 0.160 |
Why?
|
| Physical Examination | 1 | 2020 | 116 | 0.160 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 229 | 0.160 |
Why?
|
| Staphylococcal Infections | 1 | 2021 | 162 | 0.160 |
Why?
|
| Manipulation, Orthopedic | 1 | 2019 | 9 | 0.160 |
Why?
|
| Electronic Health Records | 1 | 2019 | 73 | 0.160 |
Why?
|
| Administration, Topical | 1 | 2018 | 16 | 0.160 |
Why?
|
| Sepsis | 1 | 2020 | 113 | 0.150 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 216 | 0.150 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 348 | 0.150 |
Why?
|
| Capnography | 1 | 2018 | 9 | 0.150 |
Why?
|
| Lung | 3 | 2023 | 168 | 0.150 |
Why?
|
| Bacillus anthracis | 1 | 2017 | 1 | 0.150 |
Why?
|
| Bioterrorism | 1 | 2017 | 3 | 0.140 |
Why?
|
| Ciprofloxacin | 1 | 2017 | 11 | 0.140 |
Why?
|
| Disaster Planning | 1 | 2017 | 7 | 0.140 |
Why?
|
| Renal Insufficiency | 1 | 2017 | 12 | 0.140 |
Why?
|
| Doxycycline | 1 | 2017 | 16 | 0.140 |
Why?
|
| Bandages | 1 | 2017 | 5 | 0.140 |
Why?
|
| Length of Stay | 1 | 2019 | 313 | 0.140 |
Why?
|
| Neoplasms | 1 | 2020 | 237 | 0.140 |
Why?
|
| Time Factors | 2 | 2021 | 1433 | 0.140 |
Why?
|
| Intestine, Small | 1 | 2017 | 30 | 0.140 |
Why?
|
| Odds Ratio | 1 | 2018 | 270 | 0.140 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 300 | 0.140 |
Why?
|
| Illinois | 1 | 2017 | 250 | 0.130 |
Why?
|
| Pain Measurement | 1 | 2018 | 483 | 0.130 |
Why?
|
| Infant | 1 | 2018 | 564 | 0.130 |
Why?
|
| Child, Preschool | 1 | 2018 | 641 | 0.130 |
Why?
|
| Drug Dosage Calculations | 1 | 2014 | 6 | 0.110 |
Why?
|
| Voriconazole | 1 | 2014 | 12 | 0.110 |
Why?
|
| Fluconazole | 1 | 2014 | 8 | 0.110 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 17 | 0.110 |
Why?
|
| Mycoses | 1 | 2014 | 21 | 0.110 |
Why?
|
| Triazoles | 1 | 2014 | 29 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2019 | 1890 | 0.110 |
Why?
|
| Animals | 1 | 2020 | 3642 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 43 | 0.090 |
Why?
|
| Adolescent | 1 | 2017 | 2172 | 0.090 |
Why?
|
| Acute Disease | 2 | 2025 | 176 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 676 | 0.090 |
Why?
|
| Professional Role | 2 | 2021 | 31 | 0.090 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 4777 | 0.090 |
Why?
|
| Administration, Intravenous | 2 | 2019 | 24 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 333 | 0.070 |
Why?
|
| Incidence | 2 | 2020 | 759 | 0.070 |
Why?
|
| Vertigo | 1 | 2023 | 8 | 0.050 |
Why?
|
| Pleura | 1 | 2023 | 9 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 31 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2025 | 206 | 0.050 |
Why?
|
| Glasgow Coma Scale | 1 | 2022 | 8 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 1 | 2022 | 96 | 0.050 |
Why?
|
| Linezolid | 1 | 2021 | 4 | 0.050 |
Why?
|
| Cadaver | 1 | 2022 | 375 | 0.040 |
Why?
|
| Penicillanic Acid | 1 | 2020 | 3 | 0.040 |
Why?
|
| Piperacillin | 1 | 2020 | 3 | 0.040 |
Why?
|
| Medical Records | 1 | 2020 | 33 | 0.040 |
Why?
|
| Heart Rate | 1 | 2020 | 114 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2020 | 57 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2021 | 158 | 0.040 |
Why?
|
| Critical Care | 1 | 2021 | 117 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2021 | 119 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 161 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 236 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2019 | 26 | 0.040 |
Why?
|
| Logistic Models | 1 | 2020 | 395 | 0.040 |
Why?
|
| Hospitalization | 1 | 2021 | 300 | 0.040 |
Why?
|